| Filed On | Filing |
|---|---|
| 24 Jun 2024 |
8-K/A: Financial Statements and Exhibits
To the Shareholders and the Board of Directors of AlmataBio, Inc., |
| 03 Jun 2024 |
8-K/A: Financial Statements and Exhibits
To the Shareholders and the Board of Directors of AlmataBio, Inc., |
| 11 Dec 2019 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Agreement and Plan of Merger and Reorganization (this “Agreement”), is entered into as of December 5, 2019, by and among Aevi Genomic Medicine, Inc., a Delaware corporation (the “Company”), Cerecor Inc., a Delaware corporation (“Par... |
| 19 Sep 2019 |
8-K/A: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on March 27, 2019, Cerecor Inc. (the “Company”) notified Nasdaq that the Company was no longer in compliance with Nasdaq Listing Rule 5605(b)(1), which requires the Company’s Board of Directors (the “Board”) be c... |
| 04 Dec 2018 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined statements of operations have been prepared to illustrate the effects of the acquisition of Ichorion Therapeutics, Inc. (“Ichorion”) on September 25, 2018 (“the Acquisition”), the effe... |
| 04 May 2018 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined financial information has been prepared to illustrate the effects of the acquisition of the Pediatrics Business (“Avadel Pediatrics Business”) from Avadel Pharmaceuticals plc (“Avadel”... |
| 24 Jan 2018 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined financial information has been prepared to illustrate the effects of the acquisition of TRx Pharmaceuticals LLC, including subsidiary Zylera Pharmaceuticals, LLC (the “Acquisition”). T... |
| 29 Nov 2017 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Certain Officers; Compensatory Arrangements of Certain Officers. |
| 18 Oct 2017 |
8-K/A: Notice of Delisting or Failure to Satisfy a Listing Rule
On October 17, 2017, Cerecor Inc. (the “Company”) received notice from the Nasdaq Listing Qualifications Staff (the “Staff”) confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing ... |
| 25 Aug 2017 |
8-K/A: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously reported, on February 24, 2017 the Company received a notice (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”),... |
| 07 Jul 2017 |
8-K/A: Submission of Matters to a Vote of Security Holders
On June 30, 2017, Cerecor Inc. (the “Company”) held its Annual Meeting. As of May 15, 2017, the record date for the Annual Meeting, there were 14,081,453 shares of common stock outstanding and entitled to vote. At the Annual Meeting, 11,... |
| 05 Jan 2016 |
8-K/A: Departure/Election of Directors or Officers; Compensation
In connection with his resignation as President and Chief Executive Officer and a director of the Company, Dr. Paterson and the Company entered into a separation agreement (the “Separation Agreement”), to be effective January 9, 2016 (th... |
| 29 Dec 2015 |
8-K/A: Departure/Election of Directors or Officers; Compensation
In connection with his appointment as Chief Executive Officer, Dr. Hacksell and the Company entered into an employment agreement, to be effective January 1, 2016 (the “Effective Date”). |
Loading...